A recent trial randomly allocated 1,979 men with localized prostate cancer to radiation therapy with or without neoadjuvant androgen deprivation. Despite the combination reducing prostate cancer-specific mortality by approximately 60% and producing a modest overall survival benefit in men with intermediate-risk cancers, the authors did not recommend changing the standard of care—why?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer
BMC Cancer Open Access 21 July 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wilkins, A. & Parker, C. Treating prostate cancer with radiotherapy. Nat. Rev. Clin. Oncol. 7, 583–589 (2010).
Pilepich, M. V. et al. Phase III trial of androgen suppression using goserelin in unfavourable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of the Radiation Therapy Oncology Group Protocol 85–31. J. Clin. Oncol. 15, 1013–1021 (1997).
Pilepich, M. V. et al. Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 50, 1243–1252 (2001).
Jones, C. U. et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N. Engl. J. Med. 365, 107–118 (2011).
D'Amico, A. V., Chen, M.-H., Renshaw, A. A., Loffredo, M. & Kantoff, P. W. Androgen suppression and radiation vs radiation alone for prostate cancer. JAMA 299, 289–295 (2008).
Denham, J. W. et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 12, 451–459 (2011).
Crook, J. et al. Final report of multicenter Canadian phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 73, 327–333 (2009).
Armstrong, J. G. et al. A randomized trial (Irish Clinical Oncology Research Group 97–01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 81, 35–45 (2011).
US National Library of Medicine. ClinicalTrials.gov[online], (2009).
D'Amico, A. V. et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. JAMA 280, 969–974 (1998).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Denham, J. An important piece of the localized prostate cancer puzzle?. Nat Rev Clin Oncol 8, 573–574 (2011). https://doi.org/10.1038/nrclinonc.2011.128
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.128
